Company overview
MitoRx Therapeutics is a preclinical-stage UK biotech platform company developing first-in-class small molecule therapeutics that target mitochondrial dysfunction through sulfide-signaling restoration. The company's pipeline addresses obesity, neurodegenerative diseases, neuromuscular disorders, and rare metabolic diseases, with lead programs designed for both oral and injectable administration. MitoRx has achieved platform proof-of-concept in mammalian disease models and raised $5 million in seed financing since 2022 to advance its mitochondrial-protective technology toward clinical candidates.
Mitochondrial Metabolic Modulation Platform is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include mitochondrial therapeutics, sulfide signaling, obesity treatment, neurodegenerative disease, small molecule drug development.
Structured facts
- Website
- https://www.mitorxtherapeutics.com
- Markets served
- United States & Americas
- Keywords
- mitochondrial therapeutics, sulfide signaling, obesity treatment, neurodegenerative disease, small molecule drug development
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What is MitoRx's core technology platform?
- MitoRx has developed a first-in-class, first-in-target platform using small molecules targeted to mitochondria that restore the S-persulfidation post-translational signaling system. This approach reverses mitochondrial dysfunction by acting as sulfide donors, enabling restoration of adaptive metabolism and halting disease progression in degenerative conditions.
- What therapeutic areas and indications does MitoRx focus on?
- MitoRx's internal focus areas include neurodegenerative diseases, neuromuscular disorders, and obesity. The company is also developing programs for rare metabolic diseases and inflammatory conditions. Preclinical data demonstrates utility in models of Huntington's disease, Parkinson's disease, Alzheimer's disease, and Duchenne muscular dystrophy.
- What is the current development stage and regulatory pathway?
- MitoRx is a preclinical-stage company that achieved platform proof-of-concept in Q4 2023 in mammalian disease models. The company is developing multiple asset classes with the goal of progressing clinical candidates to the clinic, with lead programs in both oral and intermittent injectable formulations for obesity.
- What differentiates MitoRx's obesity approach from GLP-1 therapies?
- MitoRx's small molecules are designed to preserve lean muscle mass while reducing fat, addressing a key limitation of standard-of-care obesity treatments. The approach targets the root cause of metabolic disease through mitochondrial metabolic modulation rather than appetite suppression.
- Where is MitoRx based and who leads the scientific team?
- MitoRx is based in Oxford and Cambridge (also referenced as Oxford and Exeter), UK. The company was built around Prof. Matt Whiteman PhD, a pioneer in mitochondrial-targeted sulfide donor technology, with a team specialized in rare diseases acceleration and intellectual property strategy.
Related editorial coverage
- Design Therapeutics' Friedreich's Ataxia Data and Vincentage's Obesity Results: A Strategic Analysis
- Lilly's Triple-Acting Obesity Drug Achieves Phase 3 Trial Goals
- Eli Lilly’s Triple-G Drug Achieves Bariatric Surgery-Level Weight Loss
- Lilly's Triple Agonist: Leading the Charge in Obesity Treatment
- Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
- Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Explore lab tools and QA/QC resources for R&D teams.
